Market Currents
Following the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for...
-
Tuesday, February 1, 2011, 7:34 AM ETFollowing the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for three, as the FDA issues a Complete Response Letter for Contrave, saying it wants another trial to rule out cardiovascular risk. After a halt, shares are down almost 70% premarket.
Other date
Latest Articles
